Skip to content
Open access

Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer

Aug 2026 · medRxiv · 0 citations
Medicine

TL;DR

MULTIPL demonstrated robust prognostic performance in external validation, identified a subgroup enriched for benefit from GNP, and enabled discovery and validation of prognostic biomarkers in metastatic PDAC, underscoring the value of the PASS-01 Challenge.

Read PDF

Similar papers

Sep 2026

Abstract A105: The PASS-01 Challenge: Comparing Biomarkers for Treatment Selection in Advanced Pancreatic Cancer in a Randomized Controlled Trial

Predictive biomarkers for first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC) have been proposed, but none have been validated using data from a randomized controlled trial (RCT), which is the only design capable of unbiased assessment of differential treatment effect (DTE)....

W. Quan, D. Henault, S. M. Hasnain et al. · 0 citations
Open access Sep 2026

A cfDNA fragmentomics-based machine learning model for predicting treatment response and recurrence in locally advanced rectal cancer after neoadjuvant chemoradiotherapy

Neoadjuvant chemoradiotherapy (nCRT) is standard treatment for locally advanced rectal cancer (LARC), but responses vary substantially. We developed Fragmentia-AI Response, a machine learning model that uses cell-free DNA (cfDNA) fragment features to predict pathological response and recurrence risk without relying on...

Kun Miao, S. Wang, Guo-Feng Sun et al. · 0 citations
Preprint Sep 2026

A Multimodal Dataset for Survival Prediction in Resected Pancreatic Ductal Adenocarcinoma

Survival research in pancreatic ductal adenocarcinoma (PDAC) is limited by the scarcity of datasets linking whole-slide histology with clinical, molecular, and long-term outcome data. We present a retrospective single-centre cohort of 302 patients who underwent PDAC resection at University Medical Center Gottingen. The...

Anh-Tien Nguyen, Mawuko Tettey, J. M. Metsch et al. · 0 citations
Open access Sep 2026

Deep learning CT signature for predicting early liver metastases in pancreatic ductal adenocarcinoma

Accurately predicting the risk of early liver metastases (ELM) and identifying patients who are most likely to benefit from neoadjuvant therapy (NAT) are critical for pancreatic ductal adenocarcinoma (PDAC). Here, we develop a Mamba-based predictive model that integrates imaging features from both the primary pancreati...

Ben Zhao, Zhi-Fang Gong, W. Xiao et al. · 0 citations
Open access Oct 2026

Machine learning model for the prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer

Breast cancer patients receiving neoadjuvant treatment may benefit from a presurgical assessment of complete response to avoid unnecessary surgeries. We aimed to develop a machine learning model that predicts pathological complete response (pCR) based on results from different image modalities as well as tumor and pati...

Eva Reisig, Lie Cai, Maria Müller et al. · 0 citations
#artificial intelligence Review Oct 2026

Transcriptome-informed multi-modal AI for predicting neoadjuvant therapy response from breast cancer biopsies

A two-stage AI model predicting pathological complete response to neoadjuvant therapy in breast cancer and transcriptome-wide inference improves discrimination over clinical variables alone or one-stage pathology models, and robustness by avoiding genomic assays'gene selection constraints are developed.

Jungkyu Park, D. Biswas, J. Cappadona et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.